Summary:
Chinook Therapeutics, Inc. / “A Phase 1, Single Center, Randomized, Placebo-Controlled, Double Blind Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CHK-336 in Healthy Volunteers”
Qualified Participants Must:
18-45 years old
No Rx meds
Hormonal birth control is ok
Non-smoker
must pass a drug screen
requires a 19-night stay at our Phase 1 unit in Cincinnati, OH plus 2 outpatient visits
Qualified Participants May Receive:
Compensation up to $8,950